ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Viking Therapeutics Inc

Viking Therapeutics Inc (VKTX)

33,69
0,26
(0,78%)
Geschlossen 31 Januar 10:00PM
33,99
0,30
(0,89%)
Nach Börsenschluss: 1:59AM

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

Current Price
33,99
Gebot
33,60
Fragen
33,99
Volumen
2.463.876
33,30 Tagesbereich 34,29
22,51 52-Wochen-Bereich 99,3999
Marktkapitalisierung
Handelsende
33,43
Handelsbeginn
34,07
Letzte Trade
30
@
33.6
Letzter Handelszeitpunkt
Finanzvolumen
US$ 83.336.801
VWAP
33,8235
Durchschnittliches Volumen (3 Mio.)
3.782.313
Ausgegebene Aktien
111.436.384
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
-43,76
Gewinn pro Aktie (EPS)
-0,77
Erlöse
-
Nettogewinn
-85,9M

Über Viking Therapeutics Inc

Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, ti... Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator. Mehr anzeigen

Sektor
Pharmaceutical Preparations
Branche
Pharmaceutical Preparations
Hauptsitz
Wilmington, Delaware, USA
Gegründet
-
Viking Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker VKTX. The last closing price for Viking Therapeutics was US$33,43. Over the last year, Viking Therapeutics shares have traded in a share price range of US$ 22,51 to US$ 99,3999.

Viking Therapeutics currently has 111.436.384 shares in issue. The market capitalisation of Viking Therapeutics is US$3,73 billion. Viking Therapeutics has a price to earnings ratio (PE ratio) of -43.76.

Option-Flow Viking Therapeutics (VKTX)

Gesamtfluss

Bullisch

Nettoprämie

235k

Calls / Puts

300,00%

Käuf. / Verkä.

300,00%

OTM / ITM

300,00%

Sweeps

0,00%

VKTX Neueste Nachrichten

Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2024 on February 5, 2025

Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2024 on February 5, 2025 PR Newswire SAN DIEGO, Jan. 29, 2025 Conference Call Scheduled for Wednesday, February 5...

Viking Therapeutics Announces Initiation of Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity

Viking Therapeutics Announces Initiation of Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity PR Newswire SAN DIEGO, Jan. 8, 2025 13-Week Study to Evaluate...

Viking Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

Viking Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference PR Newswire SAN DIEGO, Jan. 6, 2025 SAN DIEGO, Jan. 6, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking...

Viking Therapeutics Presents Results from Phase 2b VOYAGE Study of VK2809 in Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting® 2024

Viking Therapeutics Presents Results from Phase 2b VOYAGE Study of VK2809 in Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting® 2024 PR Newswire SAN DIEGO, Nov. 19, 2024 Oral Late Breaker...

Viking Therapeutics to Present Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting® 2024

Viking Therapeutics to Present Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting® 2024 PR Newswire SAN DIEGO, Nov. 12, 2024 Results...

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
1-0.57-1.6493055555634.5635.9732.77252978234.00813071CS
4-6.75-16.568483063340.7443.5530.56349464535.55484046CS
12-32.1-48.570131638766.0970.4130.56378231345.67054433CS
26-27.88-45.062227250761.8781.729530.56377118956.16818619CS
5210.2943.41772151923.799.399922.51445776362.04171549CS
15630.32826.1580381473.6799.39992.02300006036.98709372CS
26027.59431.093756.499.39992.02225407630.55868012CS

VKTX - Frequently Asked Questions (FAQ)

What is the current Viking Therapeutics share price?
The current share price of Viking Therapeutics is US$ 33,99
How many Viking Therapeutics shares are in issue?
Viking Therapeutics has 111.436.384 shares in issue
What is the market cap of Viking Therapeutics?
The market capitalisation of Viking Therapeutics is USD 3,73B
What is the 1 year trading range for Viking Therapeutics share price?
Viking Therapeutics has traded in the range of US$ 22,51 to US$ 99,3999 during the past year
What is the PE ratio of Viking Therapeutics?
The price to earnings ratio of Viking Therapeutics is -43,76
What is the reporting currency for Viking Therapeutics?
Viking Therapeutics reports financial results in USD
What is the latest annual profit for Viking Therapeutics?
The latest annual profit of Viking Therapeutics is USD -85,9M
What is the registered address of Viking Therapeutics?
The registered address for Viking Therapeutics is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
What is the Viking Therapeutics website address?
The website address for Viking Therapeutics is www.vikingtherapeutics.com
Which industry sector does Viking Therapeutics operate in?
Viking Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
FOXXFoxx Development Holdings Inc
US$ 6,355
(119,90%)
33,52M
BHILBenson Hill Inc
US$ 3,925
(118,06%)
13,52M
TECXTectonic Therapeutic Inc
US$ 55,18
(114,54%)
5,55M
AMODAlpha Modus Holdings Inc
US$ 3,2299
(109,73%)
126,59M
DOMHDominari Holdings Inc
US$ 3,61
(59,03%)
4,24M
CLEUChina Liberal Education Holdings Ltd
US$ 0,149
(-98,08%)
311,38M
CRGXCARGO Therapeutics Inc
US$ 3,39
(-74,30%)
21,21M
TDTHTrident Digital Tech Holdings Ltd
US$ 1,0159
(-58,87%)
2,46M
EVTVEnvirotech Vehicles Inc
US$ 0,338202
(-49,30%)
4,78M
IRWDIronwood Pharmaceuticals Inc
US$ 2,29
(-38,44%)
10,53M
NVDANVIDIA Corporation
US$ 124,65
(0,77%)
392,11M
CLEUChina Liberal Education Holdings Ltd
US$ 0,149
(-98,08%)
311,38M
MGOLMGO Global Inc
US$ 0,1199
(17,90%)
166,88M
SPGCSacks Parente Golf Inc
US$ 0,93
(57,63%)
129,08M
RIMEAlgorhythm Holdings Inc
US$ 0,02465
(-5,19%)
126,09M
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

Delayed Upgrade Clock